Loading
Matrisome Bio
Matrisome Bio is a Cambridge, Massachusetts start-up that aims treatments at the scaffolding around tumour cells, the extracellular matrix, rather than at the cells themselves. It is developing a radioactive medicine for lung cancer that has spread.
Also called: MATRISOME BIO, INC.
Overview
Matrisome Bio, Inc., of Cambridge, Massachusetts, describes itself as a seed-stage start-up delivering payloads to disease-associated components of the extracellular matrix of tumours and metastases, using a toolbox of nanobody-based binders. In fiscal year 2026 the National Cancer Institute funded its SBIR project on an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer (5R44CA298532-02, USD 1,013,647).
Headquarters
Cambridge, MA, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR (R44) award 5R44CA298532-02: Development of an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Stage
Startup
Website
Notes
- Read on matrisomebio.com and the NIH RePORTER record on 4 November 2026. The site names no product.
Connected
3Similar pages
cancers
fronts
technologies
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
matrisomebio.com · 1
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/